Venous Sinus Stenting for Low Pressure Gradient Stenoses in Idiopathic Intracranial Hypertension.


Journal

Neurosurgery
ISSN: 1524-4040
Titre abrégé: Neurosurgery
Pays: United States
ID NLM: 7802914

Informations de publication

Date de publication:
01 11 2022
Historique:
received: 13 12 2021
accepted: 05 06 2022
pubmed: 13 8 2022
medline: 19 10 2022
entrez: 12 8 2022
Statut: ppublish

Résumé

Medically refractory idiopathic intracranial hypertension (IIH) is frequently treated with venous sinus stenosis stenting with high success rates. Patient selection has been driven almost exclusively by identification of supraphysiological venous pressure gradients across stenotic regions based on theoretical assessment of likelihood of response. To explore the possibility of benefit in low venous pressure gradient patients. Using a single-center, prospectively maintained registry of patients with IIH undergoing venous stenting, we defined treatment groups by gradient pressures of ≤4, 5 to 8, and >8 mmHg based on the most frequently previously published thresholds for stenting. Baseline demographics, clinical, and neuro-ophthalmological outcomes (including optical coherence tomography and Humphrey visual fields) were compared. Among 53 patients, the mean age was 32 years and 70% female with a mean body mass index was 36 kg/m 2 . Baseline characteristics were similar between groups. The mean change in lumbar puncture opening pressure at 6 months poststenting was similar between the 3 groups (≤4, 5-8, and >8 mmHg; 13.4, 12.9, and 12.4 cmH 2 O, P = .47). Papilledema improvement was observed across groups at 6 months (100, 93, and 86, P = .7) as were all clinical symptoms. The mean changes in optical coherence tomography retinal nerve fiber layer (-30, -54, and -104, P = .5) and mean deviation in Humphrey visual fields (60, 64, and 67, P = .5) at 6 weeks were not significantly different. Patients with IH with low venous pressure gradient venous sinus stenosis seem to benefit equally from venous stenting compared with their higher gradient counterparts. Re-evaluation of our restrictive criteria for this potentially vision sparing intervention is warranted. Future prospective confirmatory studies are needed.

Sections du résumé

BACKGROUND
Medically refractory idiopathic intracranial hypertension (IIH) is frequently treated with venous sinus stenosis stenting with high success rates. Patient selection has been driven almost exclusively by identification of supraphysiological venous pressure gradients across stenotic regions based on theoretical assessment of likelihood of response.
OBJECTIVE
To explore the possibility of benefit in low venous pressure gradient patients.
METHODS
Using a single-center, prospectively maintained registry of patients with IIH undergoing venous stenting, we defined treatment groups by gradient pressures of ≤4, 5 to 8, and >8 mmHg based on the most frequently previously published thresholds for stenting. Baseline demographics, clinical, and neuro-ophthalmological outcomes (including optical coherence tomography and Humphrey visual fields) were compared.
RESULTS
Among 53 patients, the mean age was 32 years and 70% female with a mean body mass index was 36 kg/m 2 . Baseline characteristics were similar between groups. The mean change in lumbar puncture opening pressure at 6 months poststenting was similar between the 3 groups (≤4, 5-8, and >8 mmHg; 13.4, 12.9, and 12.4 cmH 2 O, P = .47). Papilledema improvement was observed across groups at 6 months (100, 93, and 86, P = .7) as were all clinical symptoms. The mean changes in optical coherence tomography retinal nerve fiber layer (-30, -54, and -104, P = .5) and mean deviation in Humphrey visual fields (60, 64, and 67, P = .5) at 6 weeks were not significantly different.
CONCLUSION
Patients with IH with low venous pressure gradient venous sinus stenosis seem to benefit equally from venous stenting compared with their higher gradient counterparts. Re-evaluation of our restrictive criteria for this potentially vision sparing intervention is warranted. Future prospective confirmatory studies are needed.

Identifiants

pubmed: 35960743
doi: 10.1227/neu.0000000000002095
pii: 00006123-202211000-00010
pmc: PMC10553007
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

734-740

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © Congress of Neurological Surgeons 2022. All rights reserved.

Références

Markey KA, Mollan SP, Jensen RH, Sinclair AJ. Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions. Lancet Neurol. 2016;15(1):78-91.
Rohr A, Dö L, Stingele R, Buhl R, Alfke K, Jansen O. Reversibility of venous sinus obstruction in idiopathic intracranial hypertension. AJNR Am J Neuroradiol. 2007;28(4):656-659.
Saber H, Lewis W, Sadeghi M, Rajah G, Narayanan S. Stent survival and stent-adjacent stenosis rates following venous sinus stenting for idiopathic intracranial hypertension: a systematic review and meta-analysis. Interv Neurol. 2018;7(6):490-500.
Shields LBE, Shields CB, Yao TL, Plato BM, Zhang YP, Dashti SR. Endovascular Treatment for venous sinus stenosis in idiopathic intracranial hypertension: an observational study of clinical indications, surgical technique, and long-term outcomes. World Neurosurg. 2019;121:e165-e171.
Dinkin MJ, Patsalides A. Venous sinus stenting in idiopathic intracranial hypertension: results of a prospective trial. J Neuroophthalmol. 2017;37(2):113-121.
Patsalides A, Oliveira C, Wilcox J, et al. Venous sinus stenting lowers the intracranial pressure in patients with idiopathic intracranial hypertension. J Neurointerv Surg. 2019;11(2):171-174.
Fargen KM, Liu K, Garner RM, Greeneway GP, Wolfe SQ, Crowley RW. Recommendations for the selection and treatment of patients with idiopathic intracranial hypertension for venous sinus stenting. J Neurointerv Surg. 2018;10(12):1203-1208.
Martinez-Gutierrez JC, Kole MJ, Lopez-Rivera V, et al. Primary balloon angioplasty of venous Sinus stenosis in idiopathic intracranial hypertension. Interv Neuroradiol. Published online ahead of print March 24, 2022. DOI: 10.1177/15910199221089446.
doi: 10.1177/15910199221089446
Kumpe DA, Seinfeld J, Huang X, et al. Dural sinus stenting for idiopathic intracranial hypertension: factors associated with hemodynamic failure and management with extended stenting. J Neurointerv Surg. 2017;9(9):867-874.
Ducruet AF, Crowley RW, McDougall CG, Albuquerque FC. Long-term patency of venous sinus stents for idiopathic intracranial hypertension. J Neurointerv Surg. 2014;6(3):238-242.
Fields JD, Javedani PP, Falardeau J, et al. Dural venous sinus angioplasty and stenting for the treatment of idiopathic intracranial hypertension. J Neurointerv Surg. 2013;5(1):62-68.
Asif H, Craven CL, Siddiqui AH, et al. Idiopathic intracranial hypertension: 120-day clinical, radiological, and manometric outcomes after stent insertion into the dural venous sinus. J Neurosurg. 2018;129(3):723-731.
Ahmed RM, Wilkinson M, Parker GD, et al. Transverse sinus stenting for idiopathic intracranial hypertension: a review of 52 patients and of model predictions. Am J Neuroradiol. 2011;32(8):1408-1414.
Radvany MG, Solomon D, Nijjar S, et al. Visual and neurological outcomes following endovascular stenting for pseudotumor cerebri associated with transverse sinus stenosis. J Neuroophthalmol. 2013;33(2):117-122.
Elder BD, Rory Goodwin C, Kosztowski TA, et al. Venous sinus stenting is a valuable treatment for fulminant idiopathic intracranial hypertension. J Clin Neurosci. 2015;22(4):685-689.
McDougall CM, Ban VS, Beecher J, Pride L, Welch BG. Fifty shades of gradients: does the pressure gradient in venous sinus stenting for idiopathic intracranial hypertension matter? A systematic review. J Neurosurg. 2019;130(3):999-1005.
King JO, Mitchell PJ, Thomson KR, Tress BM. Manometry combined with cervical puncture in idiopathic intracranial hypertension. Neurology. 2002;58(1):26-30.
Nicholson P, Brinjikji W, Radovanovic I, et al. Venous sinus stenting for idiopathic intracranial hypertension: a systematic review and meta-analysis. J Neurointerv Surg. 2019;11(4):380-385.
Fargen KM, Spiotta AM, Hyer M, et al. Comparison of venous sinus manometry gradients obtained while awake and under general anesthesia before venous sinus stenting. J Neurointerv Surg. 2017;9(10):990-993.
Raper DMS, Buell TJ, Chen CJ, DIng D, Starke RM, Liu KC. Intracranial venous pressures under conscious sedation and general anesthesia. J Neurointerv Surg. 2017;9(10):986-989.
Avery MB, Sambrano S, Khader Eliyas J, Eesa M, Mitha AP. Accuracy and precision of venous pressure measurements of endovascular microcatheters in the setting of dural venous sinus stenosis. J Neurointerv Surg. 2018;10(4):387-390.
Levitt MR, Hlubek RJ, Moon K, et al. Incidence and predictors of dural venous sinus pressure gradient in idiopathic intracranial hypertension and non-idiopathic intracranial hypertension headache patients: results from 164 cerebral venograms. J Neurosurg. 2017;126(2):347-353.
Farb RI, Vanek I, Scott JN, et al. Idiopathic intracranial hypertension the prevalence and morphology of sinovenous stenosis. Neurology. 2003;60(9):1418-1424.
Buell T, Ding D, Raper D, et al. Resolution of venous pressure gradient in a patient with idiopathic intracranial hypertension after ventriculoperitoneal shunt placement: a proof of secondary cerebral sinovenous stenosis. Surg Neurol Int. 2021;12:14. DOI: 10.25259/SNI_700_2020.
doi: 10.25259/SNI_700_2020
Bono F, Giliberto C, Mastrandrea C, et al. Transverse sinus stenoses persist after normalization of the CSF pressure in IIH. Neurology. 2005;65(7):1090-1093.

Auteurs

Mehmet Enes Inam (ME)

Department of Neurosurgery, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA.
Center for Precision Health, UTHealth Science Center at Houston, School of Biomedical Informatics, Houston, Texas, USA.

Juan Carlos Martinez-Gutierrez (JC)

Department of Neurosurgery, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA.

Matthew J Kole (MJ)

Department of Neurosurgery, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA.

Francisco Sanchez (F)

Eye Wellness Center, Houston, Texas, USA.

Elvira Lekka (E)

Department of Neurosurgery, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA.

Van Thi Thanh Truong (VTT)

Department of Pediatrics, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA.

Victor Lopez-Rivera (V)

Neurosurgery Department, Boston University, Boston, Massachusetts, USA.

Faheem G Sheriff (FG)

Neurology Department, Texas Tech University Health Science Center, El-Paso, Texas, USA.

Laura A Zima (LA)

Department of Neurosurgery, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA.

Claudia Pedroza (C)

Department of Pediatrics, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA.

Rosa Tang (R)

Eye Wellness Center, Houston, Texas, USA.

Ore-Ofe Adesina (OO)

Department of Neurology, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA.
Department of Ophthalmology, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA.

Allison Engstrom (A)

Department of Neurosurgery, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA.

Sunil A Sheth (SA)

Department of Neurology, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA.

Peng Roc Chen (PR)

Department of Neurosurgery, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH